EV
Evaxion Biotech A/S
EVAX · NASDAQ
$3.10 -5.05% (-$0.17)
1M +0.98%
Market Cap $19.6M
P/E Ratio -
Div. Yield -
ROE 61.39%
Bulios Fair Price
$3.72
20.0% upside
Current Price
$3.1
Undervalued Fair Value Overvalued
According to Bulios Fair Price, EVAX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
76 /100
Cheap P/S 2.61x
P/B 2.05x
P/E N/A
Growth
100 /100
Growing Book val. growth 27.08%
EPS growth N/A
Rev. growth N/A
Profitability
22 /100
Weak Gross margin 100.00%
Net margin 115.49%
Op. margin 115.98%
Quality
5 /100
Poor ROIC 46.68%
ROE 61.39%
ROA 44.65%
Debt
54 /100
Moderate Debt/Equity 0.75x
Current ratio 5.06x
Int. coverage -13.58x
Stability
31 /100
Unstable Beta 0.27x
EPS volatility 36.54%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about EVAX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Helen Katrina Tayton-Martin
Employees
46
Headquarters
Horsholm
Upcoming events
05 NOV
Earnings
Upcoming earnings report